Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) has been given an average rating of “Hold” by the six ratings firms that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $32.25.
Several analysts recently issued reports on SNNA shares. Guggenheim started coverage on Sienna Biopharmaceuticals in a report on Tuesday, December 5th. They set a “neutral” rating and a $21.00 target price on the stock. Zacks Investment Research lowered Sienna Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Finally, ValuEngine upgraded Sienna Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
NASDAQ:SNNA traded down $0.17 on Friday, hitting $18.78. 67,252 shares of the company were exchanged, compared to its average volume of 171,167. Sienna Biopharmaceuticals has a 12 month low of $13.37 and a 12 month high of $29.25. The firm has a market capitalization of $389.37 and a PE ratio of -3.62.
A number of large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its stake in Sienna Biopharmaceuticals by 13.9% in the fourth quarter. Geode Capital Management LLC now owns 45,153 shares of the company’s stock valued at $819,000 after buying an additional 5,499 shares during the period. Deutsche Bank AG raised its stake in Sienna Biopharmaceuticals by 139.8% in the fourth quarter. Deutsche Bank AG now owns 11,338 shares of the company’s stock valued at $205,000 after buying an additional 6,609 shares during the period. California State Teachers Retirement System bought a new stake in Sienna Biopharmaceuticals in the third quarter valued at approximately $182,000. Goldman Sachs Group Inc. bought a new stake in Sienna Biopharmaceuticals in the fourth quarter valued at approximately $195,000. Finally, Bank of New York Mellon Corp bought a new stake in Sienna Biopharmaceuticals in the third quarter valued at approximately $274,000. Hedge funds and other institutional investors own 41.68% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was reported by WKRB News and is the property of of WKRB News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.wkrb13.com/2018/03/31/sienna-biopharmaceuticals-inc-snna-receives-average-recommendation-of-hold-from-analysts.html.
Sienna Biopharmaceuticals Company Profile
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.